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Abstract
Background: Nocturnal leg cramps are painful, involuntary muscle contractions commonly seen in elderly.
While mostly harmless, they can severely impair quality of life and often disrupt sleep. Adverse drug effects
may be responsible for a fraction of nocturnal leg cramps but often go unrecognized, resulting in additional
prescribing intended to deal with adverse effects that might be better addressed by reduction, substitution, or
discontinuation of the offending agent.
Case presentation: An 87 year old female presented as outpatient in family medicine with nocturnal leg cramps
which had been present for five years and increasingly burdened her quality of life. She had been using quinine
200 mg once daily for symptomatic relief but the cramps kept returning with increasing intensity. During clinical
examination we found neither structural nor neurological or metabolic disorders that explained her symptoms.
When doing a medication analysis, we found that she was taking a statin together with quinine. Quinine is a
cytochrome P450 isoenzyme 3A4 inhibitor, the very enzyme which is involved in the metabolism of most statins.
Therefore the use of both substances simultaneously increases blood levels of the statin thereby increasing the
risk of side effects including symptomatic myopathy and myalgia. After discontinuing both medications, the
patient was, and remained, symptom free.
Conclusion: This case report describes a possible medication interaction that has rarely been noted in literature.
Keywords: Geriatrics, Adverse drug event, Adverse drug reaction, Aged 80, and over, Drug interaction,
Cytochrome P-450 Enzyme System
Background
Nocturnal leg cramps are painful involuntary muscle
contractions, typically in the legs or feet. They occur
during prolonged rest and often disrupt sleep. They are
common among older persons and some individuals ex-
perience multiple painful awakenings per night [1, 2].
In a study group of 365 patients with a mean age of
78.5 years, the prevalence of leg cramps was 50 %. Of
these 50 %, a fifth had had cramps for longer than
10 years plus two fifth never reported them to their
practitioner [1]. Already decades ago, quinine has been
suggested with beneficial effects in nocturnal leg
cramps [3]. Even though efficacy was reported, data is
inconsistent [4] and risk for adverse drug events such
as pancytopenia should be considered [5]. In Germany
quinine may be used for leg cramps. However, in the
US it is not approved for that indication and the U.S.
Food and Drug Administration (FDA) as well as the
German Federal Institute for Drugs and Medical
Devices published warning statements especially due to
the risk of thrombocytopenia [6, 7].
Especially older people are more likely to receive a statin
prescription. Between 2011 and 2012, 47.1 % of Americans
aged 75 and older used a prescription cholesterol-lowering
medication in the past 30 days [8]. Statins are known to
potentially induce myopathy which can lead to discon-
tinuation of treatment. Patient and drug-related factors
such as age, genetics, comorbidities and metabolism,
drug-drug interactions, drug transport respectively, can
alter the probability [9]. Statins are metabolized by
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cytochrome P450 3A4 (CYP3A4) isoenzyme. Drugs
inhibiting CYP3A4 can therefore interact with statins
such as protease inhibitors, cyclosporine, verapamil,
amiodarone, macrolide antibiotics and fibrates, which
can increase the probability for adverse drug events
(ADEs) as in this case of statin-induced myalgia [10]. A
case-report on quinine-induced acute renal failure was
published. The renal failure resulted in a combination
of hemolytic uremic syndrome and rhabdomyolysis
with disseminated intravascular coagulation with con-
cordant use of atorvastatin and quinine [11]. In
addition, the drug label of quinine sulfate provided by
the FDA recommends a reduced dosage of quinine in
renal failure due to decreased clearance. Furthermore,
the FDA indicates that quinine is an inhibitor of CYP3A4
and therefore patients receiving co-medication, especially
CYP3A4 substrates, should be monitored carefully for
increased risk of ADEs [12].
ADEs may be responsible for a fraction of nocturnal
leg cramps but often go unrecognized, resulting in
additional prescribing intended to deal with adverse ef-
fects that might be better addressed by reduction, substi-
tution, or discontinuation of the offending agent [13].
In the case of statin induced myopathy and myalgia,
additional prescription of quinine might not only be use-
less but harmful by elevating statin blood levels through
cytochrome induction thereby increasing its harmful
side effects [11].
We obtained informed consent from the patient. This
case report was structured using the CARE Statement




This 87 year old female pensioner presented for the treat-
ment of recurrent nocturnal leg cramps to our family
medicine practice. She reported a history of intense, pain-
ful sensations in the leg who were associated with sudden
muscle hardness. The symptoms regularly appeared in
both calves similarly during the night but never during
daytime. They had been occurring regularly for five years
with a low to intermediate pain intensity. Since three
weeks symptoms had been worsening and the patient
now described an “intense pain”. She had been treated
with quinine by her former family doctor in the past
and therefore began to self-medicate with quinine
200 mg once daily from her own stocks achieving only
short term symptomatic relief. She asked the consulting
doctor to give her another quinine prescription.
The patient had moved here about a year ago and
had been a patient of our practice since. She was in
very good general condition (Barthel-ADL Score 100
points) and enjoyed good quality of life despite the leg
cramps. There was no history of neurologic disorders,
hypoglycaemia, diabetes, alcoholism or hypothyroidism.
Information on earlier diagnostics concerning the leg
cramps was not available.
Her past medical history and medication is displayed
in Table 1.
Clinical findings
We conducted a clinical examination based on upto-
date’s guideline on nocturnal leg cramps [15].
The 87 old female patient presented in good physical
condition. Inspection and palpation of the musculoskeletal
system showed no physical abnormalities like muscle atro-
phy or hypertrophy, bone abnormalities, muscle tenderness
or stiffness. Skin examination of the lower extremities was
unremarkable despite scars from knee replacement on both
sides. Strong arterial pulses were palpable in all relevant
locations. Examination of the sensory as well as motor
system yielded no pathological findings.
Structural disorders such as flat feet, genu recurvatum,
and the hypermobility syndrome were ruled out.
Diagnostic assessment
Laboratory testing and other studies are usually not re-
quired in diagnosing nocturnal leg cramps [15].
Still we took a blood sample including Creatinine, GFR,
Vitamin B12 and folic acid. Renal function had deterio-
rated compared to prior laboratory findings (Creatinine
from 0.91 (range 0.51–0.95) to 1.42, GFR from 64 to 38)
(see Fig. 1). The values for tested vitamins were within
normal limits. As the blood sample had to be stored for
analysis on the following day (outpatient, office setting),
we could not analyse creatinine kinase (CK) values.
Nocturnal leg cramps are most commonly idiopathic in
nature [15]. In this case, past medical history, physical
examination and laboratory findings yielded no patho-
logical results. A graphic display is given in the timeline.
Table 1 Patient’s characteristics
Age 87 years
Symptoms Nocturnal leg cramps of moderate intensity since years.
Since three weeks intensity of symptoms increased
despite the use of quinine for symptomatic relief
Medical history myocardial infarction in 2002 with consecutive
coronary artery bypass graft (CABG)
arterial hypertension
chronic kidney disease III
knee replacement left + right.
Medication aspirin 100 mg 1-0-0
bisoprolol 2,5 mg 1-0-0
ramipril 5 mg 1-0-0
simvastatin 40 mg 0-0-1
vitamin D3 1000 IU 1-0-0
torasemide 5 mg 1-0-0
fentanyl patch 12,5 μg once every 3 days.
Self-medication: quinine200 mg once daily
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In preparing the demanded quinine prescription,
we conducted a medication interaction analysis. The
analysis showed a warning for the combination of
quinine and HMG-CoA reductase inhibitors. Quinine
is a CYP3A4 inhibitor, the very enzyme which is
involved in the metabolism of most statins [16].
Thereby it may increase blood levels of simvastatin
by reducing its first-pass metabolism. One case
report documents renal failure, rhabdomyolysis, haemo-
lytic uremic syndrome and disseminated intravascular
coagulation after ingestion of quinine along with ator-
vastatin [11].
Cramps qualify as symptomatic myopathy which is
associated with statin therapy and is dose, blood level
and cytochrome metabolism dependent [10, 17]. There-
fore we considered the combination of the statin and
quinine or the statin alone as the most likely cause of
the nocturnal leg cramps.
Therapeutic intervention
Based on these reports we discussed the possible medica-
tion interaction with the patient and gave her a resume of
the positive effects of the statin. Shared decision making
led to an immediate discontinuation of simvastatin and
quinine.
Follow up and outcomes
We reviewed the patient two and three weeks after
the discontinuation of her medication. After three
weeks she reported to having been “cramp free” for
one week for the first time in years, while renal
function was improved (Creatinine 1.03, GFR 55)
(see Fig. 1). We scheduled a consultation two months and
six months later in which the patient continued to be
without cramps.
Discussion
This report shows a case of leg cramps as a possible
result of both unnoticed medication side effects as
well as medication interaction through cytochrome
inhibition.
The discontinuation of both quinine and simvastatin
led to a complete and sustained remission of symp-
toms. Furthermore, renal function improved. With re-
spect to the patient’s age and strain we abstained
confirming the diagnosis of a drug-drug interaction
by using a challenge-dechallenge-rechallenge testing
protocol which is a limitation to this study. In
addition we did not want to re-administer quinine
which is not first-line therapy in nocturnal leg cramps
and is not licensed for the use in leg cramps in the
Fig. 1 Timeline: no legend
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US. Unfortunately simvastatin and CK levels could
not be obtained during initial blood sampling due to
limitations in laboratory analysis which is a limitation
to this study.
Discontinuing the lipid-lowering therapy may lead to
an increase in mortality [18]. One observational study
found that statin use was independently associated with
a reduction in the risk of all-cause mortality (adjusted
hazard ratio 0.89; 95 % CI 0.81–0.98; p = 0.02) [19].
Therefore, despite limited high-quality evidence, class I
recommendations have been made that all patients
undergoing CABG should receive statin therapy unless
contraindicated [20]. On the other hand, in patients who
develop intolerable muscle symptoms statin treatment
can be stopped [21]. As the patient already reached old
age with overall good quality of life which was greatly
impaired by the nocturnal leg cramps, discussing the
case with the patient, she chose to discontinue statin
therapy.
Thereby, adhered to the Good Palliative–Geriatric Prac-
tice algorithm, to assess the possibility to discontinue
medication in the elderly in accordance with a 4- step
medication decision making model [22, 23]. Following
our patient’s decisions, we were not able to proof the
diagnosis of a drug-drug interaction by using a challenge-
dechallenge-rechallenge testing protocol which is another
limitation to this study. A simple side effect of simvastatin
without cytochrome related medication interaction is an
alternative explanation for this case.
Conclusion
This case report should remind physicians first, that
symptomatic myopathy induced by statins may present
with cramp like symptoms and second, symptomatic
myopathy is dose related with quinine and other CYP3A4
inhibitors having the potential to increase statin blood
levels and thereby symptom intensity.
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